Multiple Myeloma Therapeutics - US Market Trends & Analysis

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.MARKET OVERVIEW
Hematological Cancer Therapies: A Prelude
Treatment Regimes: The Golden Rule
Multiple Myeloma: A Second Most Common Hematological Cancer
Treatment Therapies: Move Up the Learning Curve
Risk-Adapted Therapy: The New Norm of Future Treatment
New Generation Drugs in the Arsenal Against Multiple Myeloma
Velcade® (Bortezomib)
Thalomid® (Thalidomide)
Revlimid® (Lenalidomide)
Alkeran (Melphalan)
Doxil (Liposomal Doxorubicin)
Trisenox® (Arsenic trioxide)
Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons
Revlimid Overtakes Thalomid: Why?
How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows…
Revlimid Impedes Stem Cell Harvesting!!: What’s the Truth?
1st & 2nd Generation Geldanamycin Analog to Do Wonders for Myeloma Treatment
Other Trends & Issues
Approval of New Generation Drugs Push the Market Into the Bulge Bracket
Growth Fundamentals Get Stronger
Multidrug Resistance: A Challenge to Reckon With
Gene Therapy Exudes Hope
Challenges Encountered in Clinical Trials
FDA’s Antidotes
Europe Lagging Behind in Drug Approvals
Market Share Statistics
Oncology and Hematology Market
Drugs Approved & In Pipeline: A Review
Multiple Myeloma Drugs Approved by the FDA As of the Year 2008
Multiple Myeloma Drugs in Pipeline in the US As of the Year 2008
Phase III Drugs in Pipeline
Phase II Drugs in Pipeline
Phase I Drugs in Pipeline
Key Non-Profit Organizations in the US
Multiple Myeloma Research Foundation (MMRF)
National Coalition for Cancer Survivorship (NCCS)
National Marrow Donor Program (NMDP)
Oregon Health and Science University Cancer Institute
3.PRODUCT FACTS
Drugs
Lines of Treatment
4.CORPORATE DEVELOPMENTS
NICE Grants Approval for Use of Revlimid®
SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple Myeloma
CytRx to Acquire Innovive
Launch of Epoetin alfa Hexal
PDL and Bristol-Myers Signs Agreement
MNKD and LLS Conclude Joint Research Agreement
MorphoSys and DSM Enter into Agreement
StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India
ImmunoCellular Acquires Molecular Antibody Technology
US House of Representatives Sanction the Hematological Cancer Research Investment and Education Act
Bayer and Cell Therapeutics Enter into Mutual Agreement
Bristol-Myers to Take Over Kosan Biosciences
Bristol and PDL BioPharma Enter into Agreement
Gamida Cell Enters Into a Agreement with Amgen
Circadian Acquires Complete Stake in Vegenics
Takeda Acquires Millennium Pharmaceuticals
Fujimoto Pharmaceutical Receives Approval to Market Thalidomide
Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug
FDA Grants Orphan-Drug Designation to Melphalan
Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza
Clavis Initiates Phase II Trial of Elacytarabine
Gilead Sciences Commences GS 9219 Phase I Clinical Trial
AstraZeneca Carries Out AZD 0530 Phase II trial
European Commission Grants Approval of Thalidomide for Multiple Myeloma
EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma
Global Regulatory Developments for the Use of Revlimid® in Multiple Myeloma
Takeda Gains FDA Approval to Promote Velcade
Health Canada Approves VELCADE
Genzyme Receives FDA Certification for Mozobil
Celgene’s Thalidomide Pharmion Receives Marketing Authorization
GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics
Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals
Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer Drug
Aegera Therapeutics Acquires LymphoSign Inc
Velcade Gains Subsidy
Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira Pharmaceuticals
MilleGen Enters into Collaboration with LFB
Access Pharmaceuticals to Acquire Somanta
TopoTarget to Acquire Apoxis SA
Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics
Celgene Agrees to Acquisition of Pharmion
PerkinElmer Plans Acquisition of ViaCell
Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa
Johnson & Johnson Secures Contract worth US$112 Million
Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi Biopharmaceuticals
Ziopharm Commences Phase II Clinical Trial of ZIO-101
FDA Approves Pluristem’s Pre-IND Application of PLX-I
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor
Swissmedic Approves Celgene’s REVLIMID Oral Cancer Drug
Celgene’s REVLIMID Receives EU’s Marketing Authorization
FDA Approves Application of Piramal’s IND-P276 Multiple Myeloma Drug
Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade® Phase II Trial
FDA to Consider the New Drug Application Filed for Use of Doxil® Combined with Velcade® in Patients with Multiple Myeloma
Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL® and VELCADE®
Caraco’s Allopurinol Receives FDA Approval
5.MAJOR PLAYERS
Amgen Inc (USA)
Bristol-Myers Squibb Company (USA)
Kosan Biosciences, Inc. (USA)
Celgene Corporation (USA)
F. Hoffmann-La Roche Ltd Switzerland)
Genentech, Inc. (USA)
Genta Incorporated (USA)
Millennium Pharmaceuticals (USA)
Ortho Biotech Products, LP (USA)
Seattle Genetics (USA)
Ziopharm Oncology, Inc. (USA)
6.MARKET ANALYTICS
Exhibits
Table 1: Percentage Breakdown of Hematological Cancer Cases by Type in the US – 2008E
Table 2: Percentage Breakdown of Drugs Used in First Line Treatment in European Multiple Myeloma Market –
Table 3: Percentage Breakdown of Drugs Used in Second Line Treatment in European Multiple Myeloma Market –
Table 4: Percentage Breakdown of Drugs Used in Third Line Treatment in European Multiple Myeloma Market –
Table 5: Market Shares of Leading Companies in the US Market for Multiple Myeloma Therapeutics -
Table 6: Market Shares of Leading Companies in the US Market for Multiple Myeloma Therapeutics – 2013P
Table 7: Market Shares of Leading Companies in the US Market for Oncology and Hematology – 2008E
Table 8: Multiple Myeloma Therapeutics Market by Drug in the US: 2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Multiple Myeloma Therapeutics Market by Drug in the US for the Years 2009 &
Table 10: Multiple Myeloma Therapeutics Market by Line of Treatment in the US: 2007-2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Multiple Myeloma Therapeutics Market by Line of Treatment in the US for the Years 2009 &
Companies Profiled